Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vurolenatide in Short Bowel Syndrome (VIBRANT)
NCT04988997Phase 2Terminated
- Sponsor
- Innovate Biopharmaceuticals
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vurolenatide in short bowel syndrome (SBS) (4 arms), sponsored by Innovate Biopharmaceuticals. Primary endpoint: 24hr Total Stool Output Volume at 10 weeks. Started Jun 2021; status: terminated.
02
Drugs
vurolenatide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04988997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988997.